A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)
NCT ID: NCT01285752
Last Updated: 2016-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
240 participants
INTERVENTIONAL
2011-02-28
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)
NCT00902369
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
NCT07276581
First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis
NCT01611688
A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients
NCT02405780
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
NCT03025308
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
AK106-001616
2
AK106-001616
3
Active comparator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AK106-001616
AK106-001616
Active comparator
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stable dose of methotrexate (at least 12 weeks)
Exclusion Criteria
* Abnormal screening laboratory test values considered to be clinically significant
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asahi Kasei Pharma Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hlučín, , Czechia
Hostivice, , Czechia
Prague, , Czechia
Uherské Hradiště, , Czechia
Zlín, , Czechia
Berlin, , Germany
Frankfurt, , Germany
Hamburg, , Germany
Balatonfüred, , Hungary
Budapest, , Hungary
Debrecen, , Hungary
Bialystok, , Poland
Elblag, , Poland
Lublin, , Poland
Poznan, , Poland
Warsaw, , Poland
Bratislava, , Slovakia
Martin, , Slovakia
Donetsk, , Ukraine
Kharkiv, , Ukraine
Kyiv, , Ukraine
Ternopil, , Ukraine
Vinnytsa, , Ukraine
Zaporizhzhia, , Ukraine
Cambridge, , United Kingdom
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AK106 II-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.